Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v14-EN Version v8-EN
Language English English
Date Updated 2020-12-12 2020-11-24
Drug Identification Number 02230248 02230248
Brand name LUPRON DEPOT LUPRON DEPOT
Common or Proper name Lupron depot 22.5 mg Lupron depot 22.5 mg
Company Name ABBVIE CORPORATION ABBVIE CORPORATION
Ingredients LEUPROLIDE ACETATE LEUPROLIDE ACETATE
Strength(s) 22.5MG 22.5MG
Dosage form(s) POWDER FOR SUSPENSION, SUSTAINED-RELEASE POWDER FOR SUSPENSION, SUSTAINED-RELEASE
Route of administration INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 syringe 1 syringe
ATC code L02AE L02AE
ATC description HORMONES AND RELATED AGENTS HORMONES AND RELATED AGENTS
Reason for shortage Disruption of the manufacture of the drug. Delay in shipping of the drug.
Anticipated start date 2020-10-12 2020-10-12
Actual start date 2020-12-11 2020-12-18
Estimated end date 2020-12-11 Unknown
Actual end date 2020-12-11
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments We have been working with the manufacturing facility to increase production of LUPRON DEPOT and we will continue to distribute supplies as they become available. As production of LUPRON DEPOT continues to increase, we expect inventory of all formulations to stabilize shortly. AbbVie wishes to assure you that we are your primary source of accurate and timely information related to our inventory shortage. The shortage is temporary, and the safety and efficacy of LUPRON DEPOT were not compromised. We have been working with the manufacturing facility to increase production of LUPRON DEPOT and we will continue to distribute supplies as they become available. As production of LUPRON DEPOT continues to increase, we expect inventory in all formulations to stabilize shortly. AbbVie wishes to assure you that we are your primary source of accurate and timely information related to our inventory shortage. The shortage is temporary, and the safety or efficacy of LUPRON DEPOT was not compromised nor affected by the delay.
Health Canada comments